Preparation and characterization of dialkylphosphoryl-obidoxime conjugates, potent anticholinesterase derivatives that are quickly hydrolyzed by human paraoxonase (PON1192Q)

Biochemical Pharmacology

Volumn 74, Issue 9, 2007, Pages 1390-1400

  Stenzel, J ^a   Worek, F ^b   Eyer, P ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

Author keywords

Acetylcholinesterase; Kinetic constants; Obidoxime; Paraoxonase; Phenotypes; Phosphoryl oximes

Indexed keywords

ACETYLCHOLINESTERASE; ALLOENZYME; ARGININE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CHOLINESTERASE INHIBITOR; DIETHYLPHOSPHORYL OBIDOXIME; DIISOPROPYLPHOSPHORYL OBIDOXIME; DIMETHYLPHOSPHORYL OBIDOXIME; DYFLOS; HYDROLASE; METHANOL; NITROGEN; OBIDOXIME; ORGANOPHOSPHORUS COMPOUND; OXIME DERIVATIVE; PARAOXON; PHOSPHORYLATED OXIME DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONJUGATE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME SYNTHESIS; ERYTHROCYTE MEMBRANE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; ARYLDIALKYLPHOSPHATASE; CHOLINESTERASE INHIBITORS; CHOLINESTERASE REACTIVATORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME STABILITY; ERYTHROCYTE MEMBRANE; HUMANS; HYDROLYSIS; METHANOL; OBIDOXIME CHLORIDE; ORGANOPHOSPHORUS COMPOUNDS; PLASMA;

EID: 34548827069     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.07.013     Document Type: Article

References (66)

1. Wilson I.B., and Ginsburg S. A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase. Biochim Biophys Acta 18 (1955) 168-170
2. Hackley Jr. B.E., Steinberg G.M., and Lamb J.C. Formation of potent inhibitors of AChE by reaction of pyridinaldoximes with isopropyl methylphosphonofluoridate (GB). Arch Biochem Biophys 80 (1959) 211-214
3. Lamb J.C., Steinberg G.M., and Hackley J.B.E. Isopropyl methylphosphonylated bisquaternary oximes; powerful inhibitors of cholinesterase. Biochim Biophys Acta 89 (1964) 174-176
4. Lamb J.C., Steinberg G.M., Solomon S., and Hackley Jr. B.E. Reaction of 4-formyl-1-methylpyridinium iodide oxime with isopropyl methylphosphonofluoridate. Biochemistry 4 (1965) 2475-2484
5. Ashani Y., Bhattacharjee A.K., Leader H., Saxena A., and Doctor B.P. Inhibition of cholinesterases with cationic phosphonyl oximes highlights distinctive properties of the charged pyridine groups of quaternary oxime reactivators. Biochem Pharmacol 66 (2003) 191-202
6. Steinberg G.M., and Solomon S. Decomposition of a phosphonylated pyridinium aldoxime in aqueous solution. Biochemistry 5 (1966) 3142-3150
7. Blanch J.H. Stability of N-heterocyclic oxime derivatives. Part V. Kinetics of the reaction of 2-hydroxyiminomethyl-1-methylpyridinium iodide and isopropyl methylphosphonofluoridate in water at 15, 25 and 35 °C and at pH 5.7-7.7. J Chem Soc B (1969) 1172-1178
8. Hagedorn I., Gündel W.H., and Schoene K. Reaktivierung phosphorylierter Acetylcholin-Esterase mit Oximen: Beitrag zum Studium des Reaktionsablaufes. Arzneim Forsch 19 (1969) 603-606
9. Hagedorn I., Stark I., and Lorenz H.P. Reaktivierung phosphorylierter Acetylcholin-Esterase-Abhängigkeit von der Aktivator-Acidität. Angew Chem 84 (1972) 354-356
10. Aldridge W.N., and Reiner E. Enzyme inhibitors as substrates. Interactions of esterases with esters of organophosphorus and carbamic acids vol. 26 (1972), North-Holland Publ. Co., Amsterdam
11. Schoene K. Reaktivierung von O,O-Diäthylphosphoryl-Acetylcholinesterase. Reaktivierungs-Rephosphorylierungs-Gleichgewicht. Biochem Pharmacol 21 (1972) 163-170
12. Nenner M. Phosphonylierte Aldoxime. Hemmwirkung auf Acetylcholinesterase und hydrolytischer Abbau. Biochem Pharmacol 23 (1974) 1255-1262
13. De Jong L.P.A., and Ceulen D.I. Anticholinesterase activity and rate of decomposition of some phosphylated oximes. Biochem Pharmacol 27 (1978) 857-863
14. Harvey B., Scott R.P., Sellers D.J., and Watts P. In vitro studies on the reactivation by oximes of phosphylated acetylcholinesterase. I. On the reactions of P2S with various organophosphates and the properties of the resultant phosphylated oximes. Biochem Pharmacol 35 (1986) 737-744
15. Eyer P., and Worek F. Oximes. In: Sidell F.R. (Ed). Chemical warfare agents (2007), John Wiley & Sons, Chichester 305-329
16. Schoene K. Kinetic studies on chemical reactions between acetylcholinesterase, toxic organophosphates and pyridinium oximes. In: SIPRI (Ed). Medical protection against chemical-warfare agents (1976), Almqvist & Wiksell, Stockholm, Sweden 88-100
17. Wolthuis O.L., and Cohen E.M. The effects of P2S, TMB4 and LüH6 on the rat phrenic nerve diaphragm preparation treated with soman or tabun. Biochem Pharmacol 16 (1967) 361-367
18. Barstad J.A.B., Lilleheil G., and Skobba T.J. Phosphylated oximes. Some pharmaco-toxicological and biochemical features. Arch Int Pharmacodyn 179 (1969) 352-363
19. Kiderlen D., Eyer P., and Worek F. Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolysed by human paraoxonase (PON1). Biochem Pharmacol 69 (2005) 1853-1867
20. Kiderlen D., Worek F., Klimmek R., and Eyer P. The phosphoryl oxime-destroying activity of human plasma. Arch Toxicol 74 (2000) 27-32
21. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., and Furlong C.E. The effect of human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14 (1996) 334-336
22. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., and Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3 (1993) 73-76
23. Adkins S., Gan K.N., Mody M., and La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52 (1993) 598-608
24. Richter R.J., and Furlong C.E. Determination of paraoxonase (PON 1) status requires more than phenotyping. Pharmacogenetics 9 (1999) 745-753
25. Luo C., Saxena A., Smith M., Garcia G., Radic Z., Taylor P., et al. Phosphoryl oxime inhibition of acetylcholinesterase during oxime reactivation is prevented by edrophonium. Biochemistry 38 (1999) 9937-9947
26. Worek F., Eyer P., Kiderlen D., Thiermann H., and Szinicz L. Effect of human plasma on the reactivation of sarin-inhibited human erythrocyte acetylcholinesterase. Arch Toxicol 74 (2000) 21-26
27. Kiderlen D., Meischner V., Worek F., and Eyer P. Phosphoryl oxime-hydrolase in human serum influences oxime effectiveness in organophosphate poisoning. Drug Metab Rev 33 Suppl 1 (2001) 110
28. Eyer P., Kiderlen D., Stenzel J., Thiermann H., and Worek F. Paraoxonase polymorphism. A modifying factor that influences oxime effectiveness. Clin Toxicol 44 (2006) 440-441
29. Dodge J.T., Mitchell C., and Hanahan D.J. The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch Biochem Biophys 100 (1963) 119-130
30. Worek F., Thiermann H., Szinicz L., and Eyer P. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem Pharmacol 68 (2004) 2237-2248
31. Worek F., Mast U., Kiderlen D., Diepold C., and Eyer P. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 288 (1999) 73-90
32. Worek F., Eyer P., and Szinicz L. Inhibition, reactivation, and aging kinetics of cyclohexylmethylphosphonofluoridate-inhibited human cholinesterases. Arch Toxicol 72 (1998) 580-587
33. Lockridge O., and Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurotoxicology 21 (2000) 113-126
34. Furlong C.E., Richter R.J., Seidel S.L., and Motulsky A.G. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 43 (1988) 230-238
35. Bernt E., and Gutmann I. Äthanol. Bestimmung mit Alkohol-Dehydrogenase und NAD. In: Bergmeyer H.U. (Ed). Methoden der enzymatischen Analyse vol. II (1970), Verlag Chemie, Weinheim 1457-1460
36. Segel I.H. Enzym kinetics (1975), Wiley & Sons, New York
37. Worek F., Szinicz L., Eyer P., and Thiermann H. Evaluation of oxime efficacy in nerve agent poisoning: development of a kinetic-based dynamic model. Toxicol Appl Pharmacol 209 (2005) 193-202
38. Eckerson H.W., Romson J., Wyte C., and La Du B.N. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 35 (1983) 214-227
39. Chiu Y.C., Main A.R., and Dauterman W.C. Affinity and phosphorylation constants of a series of O,O-dialkyl malaoxons and paraoxons with acetylcholinesterase. Biochem Pharmacol 18 (1969) 2171-2177
40. Barak D., Ordentlich A., Bromberg A., Kronman C., Marcus D., Lazar A., et al. Allosteric modulation of acetylcholinesterase activity by peripheral ligands involves a conformational transition of the anionic subsite. Biochemistry 34 (1995) 15444-15452
41. Rosenfeld C.A., and Sultatos L.G. Concentration-dependent kinetics of acetylcholinesterase inhibition by the organophosphate paraoxon. Toxicol Sci 90 (2006) 460-469
42. Mueller R.F., Hornung S., Furlong C.E., Anderson J., Giblett E.R., and Motulsky A.G. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am J Hum Genet 35 (1983) 393-408
43. Brackley M., Carro-Ciampi G., Stewart D.J., Lowden J.A., Ray A.K., and Kalow W. Stability of the paraoxonase phenotyping ratio in collections of human sera with differing storage times. Res Commun Chem Pathol Pharmacol 41 (1983) 65-78
44. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
45. Geldmacher-von Mallinckrodt M., and Diepgen T.L. The human serum paraoxonase-polymorphism and specificity. Toxicol Environ Chem 18 (1988) 79-196
46. Costa L.G., Vitalone A., Cole T.B., and Furlong C.E. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69 (2005) 541-550
47. Briseno-Roa L., Hill J., Notman S., Sellers D., Smith A.P., Timperley C.M., et al. Analogues with fluorescent leaving groups for screening and selection of enzymes that efficiently hydrolyze organophosphorus nerve agents. J Med Chem 49 (2006) 246-255
48. Worek F., Diepold C., and Eyer P. Dimethylphosphoryl-inhibited human cholinesterases: inhibition, reactivation, and aging kinetics. Arch Toxicol 73 (1999) 7-14
49. Leader H., Vincze A., Manisterski B., Rothschild N., Dosoretz C., and Ashani Y. Characterization of O,O-diethylphosphoryl oximes as inhibitors of cholinesterases and substrates of phosphotriesterases. Biochem Pharmacol 58 (1999) 503-515
50. Smolen A., Eckerson H.W., Gan K.N., Hailat N., and La Du B.N. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Dispos 12 (1991) 107-112
51. Furlong C.E., Richter R.J., Seidel S.L., Costa L.G., and Motulsky A.G. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 180 (1989) 242-247
52. Debord J., Dantoine T., Bollinger J.-C., Abraham M.H., Verneuil B., and Merle L. Inhibition of arylesterase by aliphatic alcohols. Chem Biol Interact 113 (1998) 105-115
53. Furlong C.E., Li W.-F., Shih D.M., Lusis A.J., Richter R.J., and Costa L.G. Genetic factors in susceptibility: serum PON1 variation between individuals and species. Hum Ecol Risk Assess 8 (2002) 31-43
54. Draganov D.I., and La Du B.N. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's Arch Pharmacol 369 (2004) 78-88
55. Khersonsky O., and Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005) 6371-6382
56. Aharoni A., Gaidukov L., Khersonsky O., McQ Gould S., Roodveldt C., and Tawfik D.S. The 'evolvability' of promiscuous protein functions. Nat Genet 37 (2005) 73-76
57. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11 (2004) 412-419
58. Hassett C., Richter R.J., Humbert R., Chapline C., Crabb J.W., Omiecinski C.J., et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30 (1991) 10141-10149
59. Reddy S.T., Wadleigh D.J., Grijalva V., Ng C., Hama S., Gangopadhyay A., et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21 (2001) 542-547
60. Zech R., and Chemnitius J.M. PON1 in different species. In: Furlong CE (Ed). Paraoxonase (PON1) in health disease (2002), Kluwer Academic Publishers, Boston 137-163
61. Buckley N.A., Dawson A.H., and Whyte I.M. Organophosphate poisoning: peripheral vascular resistance-a measure of adequate atropinization. Clin Toxicol 32 (1994) 61-68
62. Lamping K.G., Wess J., Cui Y., Nuno D.W., and Faraci F.M. Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol 24 (2004) 1253-1258
63. Brophy V.H., Jarvik G.P., and Furlong C.E. PON1 polymorphism. In: Furlong C.E. (Ed). Paraoxonase (PON1) in health and disease: basic and clinical aspects (2003), Kluwer Academic Publications, Boston 52-77
64. Worek F., Bäcker M., Thiermann H., Szinicz L., Mast U., Klimmek R., et al. Reappraisal of indications and limitations of oxime therapy in organophosphate poisoning. Hum Exp Toxicol 16 (1997) 466-472
65. Ordentlich A., Barak D., Kronman C., Ariel N., Segall Y., Velan B., et al. The architecture of human acetylcholinesterase active center probed by interactions with selected organophosphate inhibitors. J Biol Chem 271 (1996) 11953-11962
66. Main A.R., and Iverson F. Measurement of the affinity and phosphorylation constants governing irreversible inhibition of cholinesterases by di-isopropyl phosphorofluoridate. Biochem J 100 (1966) 525-531